Series of experiments also were performed to define the degree that co-treatment with 4SP65 enhances the anticancer efficacy and overcomes drug resistance (i) to cisplatin, as a representative cytotoxic chemotherapeutic, and (ii) to gefitinib, as a representative TKI targeting epidermal growth factor receptor (EGFR) mutations, in relevant panels of human cancer cell lines. This evidence concerns the gene EGFR and cancer.